Tuesday, February 17, 2009


NOTE: Today's post is not my best effort at explaining the difficult topic of tumor speciation. Since writing this post, I have produced a revised and improved explanation, entitled Tumor Speciation Revisited.

On February 12, the world celebrated the 200th anniversary of Charles Darwin's birth. Darwin is best known for explaining speciation; how life on earth diversifies into distinct types of organisms. Each species shares a characteristic set of traits that separate the species from all other species on earth. One of the most curious aspects of speciation is member uniqueness: every species is composed of members that are different from every other member of the same species. If each species is composed of genetically diverse members, how can we think in terms of "sameness" among the members of a species?

Speciation is a general phenomenon, not confined to animals. For example, the field of cancer research deals with many different kinds (species) of tumors. The phenomenon of tumor speciation is basically the same as the problem of animal speciation. Tumors, like animals, occur as highly characteristic species, but every tumor is genetically unique, different from every other tumor that has ever occurred or that will ever occur.

Although there are many kinds of tumors that can arise in humans and other animals, pathologists (the people who render diagnoses on tissue specimens) are adept at assigning names to every tumor occurrence: Warthin's tumor of salivary gland, fibrolamellar carcinoma of liver, papillary carcinoma of thyroid, carcinoid tumor of appendix, and many others. Each kind of tumor has a characteristic appearance when it is viewed under a microscope. Pathologists can instantly render a specific diagnosis on most human tumors. Genetic analyses of cancers conducted over the past decade have shown us that cancer is a complex disease, with tumors accumulating thousands of different genetic alterations as they grow. This being the case, why do we encounter distinctive tumor species? Should we not expect a free-for-all of infinitely diverse, unique tumors? In addition, we now know that tumors continue to collect genetic changes over time. Should we not expect tumors to change their type over time, one day seeming to be a carcinoma (tumor of epithelium), and another day seeming to be a lymphoma (tumor of the immune system) or a sarcoma (tumor of the connective tissues)?

In fact, this never occurs. Just as a cat never becomes a dog, and a hamster never becomes a frog; a lymphoma (a tumor of lymph cells) never becomes an adenocarcinoma (a tumor of glandular epithelial cells), and a melanoma (a tumor of melanin producing cells of the skin) never becomes a glioma (a tumor of the central nervous system cells).

How do we reconcile the uniqueness of every tumor with the constraints of tumor speciation?

This problem is fundamentally the same problem as animal speciation. In the case of animals, speciation occurs because of the genetic diversity among the different members of a species. New species arise from mating among a subpopulation of a species that preserves genetic traits that are expressed within the subpopulation, and that are not expressed in the general population of the species. If the individual animals within a population were genetically identical, and could not express new traits in subpopulations, speciation, would not occur. When a new species appears, it has some properties of the parent species, but it also has traits that distinguish it from the parent species and every other species on earth.

In cancers, the malignant phenotype is acquired primarily through genetic alterations, but the type of a tumor is acquired through cell lineage determined by epigenetic alterations.

The human body has several hundred different kinds of cells, and these cells pass through many different developmental stages on their way to becoming the fully functional cells we find in adult bodies. Every neoplasm, despite its genetic uniqueness, has a set of properties determined by the epigenetic modifications that characterize its cell-type of origin. These epigenetic features will be shared by other tumors arising from the same type of cell. Each of the many different species of tumors occurring in humans and animals has a microscopic appearance and biological behavior that has traits of the type of cell from which it arose. In addition, each type of cancer has a set of neoplastic traits whose expression is constrained by the pre-existing cellular pathways inherited from the parent cell type.

This explains how it is possible that every tumor that has ever occurred is a unique biological entity; and yet, every tumor that has ever occurred can be classified as a member of a distinctive species that shares morphologic and biological features with every other tumor of the same kind.

I have heard it said that Charles Darwin's "On the Origin of Species," has negligible impact on our daily lives. This is not so. Aside from its enormous impact on every aspect of the natural sciences, it is the basis for much of modern medicine: genetics, molecular biology, and pharmacology. Just as our knowledge of animal speciation permits us to organize and make sense of life on this planet, our knowledge of tumor speciation permits us to organize tumors into classes that share a common epigenetic (developmental) lineage. Cells of a common lineage (class) will likely share the same genetically altered pathways that determine their malignant properties. Drugs that control these pathways in any given tumor, will likely control the same pathways in all tumors of a common class. When we know the class of a species of tumor, we have a way of developing cures that apply to every species in the class.

- © 2009 Jules J. Berman

In June, 2014, my book, entitled Rare Diseases and Orphan Drugs: Keys to Understanding and Treating the Common Diseases was published by Elsevier. The book builds the argument that our best chance of curing the common diseases will come from studying and curing the rare diseases.

I urge you to read more about my book. There's a generous preview of the book at the Google Books site.

tags: biology of rare diseases, common diseases, genetic disease, disease genetics, orphan diseases, orphan drugs, rare disease organizations, rare disease research, rare diseases, rare disease funding, rare disease research, funding for rare diseases, importance of rare diseases, funding opportunities, books about rare diseases, books about orphan drugs, orphan drug development, pathology of rare diseases, complex diseases, neoplasm, classification, cancer, tumour